Antidiabetic interaction warning

Pioglitazone is licensed for use as monotherapy, with metformin and/or a sulfonylurea, and with insulin | SCIENCE PHOTO LIBRARY
Pioglitazone is licensed for use as monotherapy, with metformin and/or a sulfonylurea, and with insulin | SCIENCE PHOTO LIBRARY

The MHRA has reminded prescribers that combined use of pioglitazone and insulin may be associated with an increased risk of cardiac failure, especially in patients with underlying risk factors for this condition.

If the combination is used, patients should be observed for signs and symptoms of heart failure, weight gain, and oedema. Pioglitazone should be discontinued if any deterioration in cardiac status occurs.

Rosiglitazone, another member of the thiazolidinedione class, was withdrawn in 2010 in light of evidence linking it to adverse cardiovascular outcomes.

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in